Old Web
English
Sign In
Acemap
>
Paper
>
PV-142 Neoadjuvantes Osimertinib mit/ohne Chemotherapie vs Chemotherapie bei EGFR-mutiertem resektablem NSCLC: NeoADAURA
PV-142 Neoadjuvantes Osimertinib mit/ohne Chemotherapie vs Chemotherapie bei EGFR-mutiertem resektablem NSCLC: NeoADAURA
2021
M Beshay
M Tsuboi
Walter Weder
C. Escriu
Collin M. Blakely
Jing He
Sanja Dacic
Y. Yatabe
L. Zeng
Andrew Walding
Jamie E. Chaft
D. Scriba
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]